687639-03-8

Basic information

• Product Name: Acetamide, N-(3-bromo-4-oxocyclohexyl)-
• CAS NO: 687639-03-8
• Molecular Formula: C8H12BrNO2
• Molecular Weight: 234.093
• Mol File: 687639-03-8.mol

Chemical Properties

• CAS DataBase Reference: Acetamide, N-(3-bromo-4-oxocyclohexyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Acetamide, N-(3-bromo-4-oxocyclohexyl)-(687639-03-8)
• EPA Substance Registry System: Acetamide, N-(3-bromo-4-oxocyclohexyl)-(687639-03-8)

Safety Data

• Hazardous Substances Data: 687639-03-8(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
Acetamide, N-(3-bromo-4-oxocyclohexyl)is used as a building block in organic synthesis for the creation of various biologically active molecules. Its unique structure allows for the formation of new compounds with potential applications in various fields.
Used in Pharmaceutical Research:
In the pharmaceutical industry, Acetamide, N-(3-bromo-4-oxocyclohexyl)is utilized for the synthesis of new drugs and medical treatments. Its structural features make it a valuable component in the development of innovative therapeutic agents.
Safety Precautions:
As with any chemical compound, proper handling and safety precautions should be followed when working with Acetamide, N-(3-bromo-4-oxocyclohexyl)to ensure the safety of researchers and the surrounding environment.

Upstream product

• 23363-88-4 trans-N-acetyl-4-hydroxycyclohexylamine 
• 27514-08-5 N-(4-oxocyclohexyl)acetamide 

Downstream Products

• 106006-83-1 2,6-diamino-4,5,6,7-tetrahydro-benzthiazole 
• 106092-11-9 (R)-4,5,6,7-tetrahydrobenzo[1,2-d]thiazole-2,6-diamine 
• 106092-09-5 (S)-4,5,6,7-tetrahydrobenzo[d]thiazol-2,6-diamine 
• 1262552-31-7 1-((S)-2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-3-(2-fluorophenyl)thiourea 
• 1262552-30-6 1-((S)-2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-3-(3-methoxyphenyl)thiourea 
• 1262552-29-3 1-((S)-2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-3-(3-chlorophenyl)thiourea 
• 1262552-28-2 1-((S)-2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-3-(4-fluorophenyl)thiourea 
• 1262552-27-1 1-((S)-2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-3-(4-methoxyphenyl)thiourea 
• 1262552-35-1 1-((S)-2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-3-phenylthiourea 
• 1262552-34-0 1-((S)-2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-3-(4-chlorophenyl)thiourea 
• 1262552-33-9 1-((S)-2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-3-(2,4-dichlorophenyl)thiourea 
• 1262552-32-8 1-((S)-2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-3-(2-chlorophenyl)thiourea 
• 104617-50-7 N-(2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)acetamide hydrobromide 
• 372982-92-8 tert-butyl 2-[[(1R)-2-((2S)-{[(2-amino-4,5,6,7-tetrahydro-1,3-benzothiazol-6-yl)amino]carbonyl}pyrrolidinyl)-1-(cyclohexylmethyl)-2-oxoethyl](tert-butyoxycarbonyl)amino]acetate 

Relevant articles and documents

Preparation method of pramipexole intermediate 2, 6-diamino-4, 5, 6, 7-tetrahydrobenzothiazole

The invention discloses a preparation method of pramipexole intermediate 2, 6-diamino-4, 5, 6, 7-tetrahydrobenzothiazole. According to the method, 4-acetamido cyclohexanol is taken as a starting material, hydrobromic acid is taken as an oxidizing agent an

Crystallization process of diamino -4, 5, 6, 7- tetrahydrobenzothiazole

Reaction and formation, of the product, with acetone as a reaction solvent, takes place in acetone as a reaction solvent to give the product, as a raw material, with acetone as a reaction solvent to obtain the mixed rotation product, and then recrystallize the reaction solvent with water: to obtain the reaction . Example, shows that the reaction time, is greatly shortened by taking the product, as a reaction solvent by taking acetone as a reaction solvent as a raw material A; dropwise to obtain the reaction and the reaction of the reaction, solvent with water and dissolving: dropwise with acetone as a reaction solvent in step A as a reaction solvent in an existing production process by, acetone, L - taking acetone as a, reaction solvent to prepare a reaction solvent for, the whole process, to prepare a crystal, by taking acetone as, a reaction solvent to prepare a reaction solvent by taking acetone as a reaction solvent to prepare a. reaction solvent by taking acetone as a reaction solvent.

Industrial preparation method of 2,6-diamino-4,5,6,7-tetrahydro-benzothiazole

The invention discloses a preparation method of 2,6-diamino-4,5,6,7-tetrahydro-benzothiazole suitable for industrial production, wherein 2,6-diamino-4,5,6,7-tetrahydro-benzothiazole is prepared by using p-acetamido cyclohexanone as a raw material through a one-pot method. According to the method, liquid bromine and acetic acid are not used in the production and preparation process, the 6-acetamido-2-amino-4,5,6,7-tetrahydro-benzothiazole can be prepared through a one-pot method, post-treatment operation is easy and convenient, the labor cost is saved, and the production cost is greatly reduced. The 2,6-diamino-4,5,6,7-tetrahydro-benzothiazole prepared by the method is high in yield, good in purity and suitable for industrial production.

Discovery of 4,5,6,7-Tetrahydrobenzo[1,2- d ]thiazoles as Novel DNA Gyrase Inhibitors Targeting the ATP-Binding Site

Bacterial DNA gyrase and topoisomerase IV are essential enzymes that control the topological state of DNA during replication and validated antibacterial drug targets. Starting from a library of marine alkaloid oroidin analogues, we identified low micromolar inhibitors of Escherichia coli DNA gyrase based on the 5,6,7,8-tetrahydroquinazoline and 4,5,6,7-tetrahydrobenzo[1,2-d]thiazole scaffolds. Structure-based optimization of the initial hits resulted in low nanomolar E. coli DNA gyrase inhibitors, some of which exhibited micromolar inhibition of E. coli topoisomerase IV and of Staphylococcus aureus homologues. Some of the compounds possessed modest antibacterial activity against Gram positive bacterial strains, while their evaluation against wild-type, impA and ΔtolC E. coli strains suggests that they are efflux pump substrates and/or do not possess the physicochemical properties necessary for cell wall penetration. Our study provides a rationale for optimization of this class of compounds toward balanced dual DNA gyrase and topoisomerase IV inhibitors with antibacterial activity.

Synthesis and identification of a new class of (S)-2,6-diamino-4,5,6,7- tetrahydrobenzo[d]thiazole derivatives as potent antileukemic agents

Benzothiazoles are multitarget agents with broad spectrum of biological activity. Among the antitumor agents discovered in recent years, the identification of various 2-(4-aminophenyl) benzothiazoles as potent and selective antitumor drugs against different cancer cell lines has stimulated remarkable interest. Some of the benzothiazoles are known to induce cell cycle arrest, activation of caspases and interaction with DNA molecule. Based on these interesting properties of benzothiazoles and to obtain new biologically active agents, a series of novel 4,5,6,7-tetrahydrobenzo[d]thiazole derivatives 5(a-i) were synthesized and evaluated for their efficacy as antileukemic agents in human leukemia cells (K562 and Reh). The chemical structures of the synthesized compounds were confirmed by 1H NMR, LCMS and IR analysis. The cytotoxicity of these compounds were determined using trypan blue exclusion, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and lactate dehydrogenase (LDH) assays. Results showed that, these compounds mediate a significant cytotoxic response to cancer cell lines tested. We found that the compounds having electron withdrawing groups at different positions of the phenyl ring of the thiourea moiety displayed significant cytotoxic effect with IC50 value less than 60 μM. To rationalize the role of electron withdrawing group in the induction of cytotoxicity, we have chosen molecule 5g (IC 50 ～15 μM) which is having chloro substitution at ortho and para positions. Flow cytometric analysis of annexin V-FITC/propidium iodide (PI) double staining and DNA fragmentation suggest that 5g can induce apoptosis. Springer Science + Business Media, LLC 2009.

FUSED OXAZOLES and THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS

The present invention relates to compounds comprising fused oxazole or thiazole derivatives of formula (I), processes for preparing them, pharmaceutical compositions comprising said compounds and their uses as H3-receptor ligands, wherein A is a cyclic amine which is linked to the propylene group via an amino nitrogen; B is selected from the group consisting of heteroaryl, 5-8-membered heterocycloalkyl, 5-8-membered cycloalkyl; X is either N or CH; Y is either O or S.

Novel non-covalent thrombin inhibitors incorporating P1 4,5,6,7-tetrahydrobenzothiazole arginine side chain mimetics

The design, synthesis and biological activity of a series of novel non-covalent D-Phe-Pro-Arg motif-based thrombin inhibitors incorporating 4,5,6,7-tetrahydrobenzothiazol-2-amine as a novel arginine surrogate are described. Compound 9, the most potent in

PROCESS FOR PREPARING 2,6-DIAMINO-4,5,6,7-TETRAHYDRO-BENZOTHIAZOLE

2,6-diamino-4,5,6,7-tetrahydro-benzothiazole, which is useful for making pramipexole, is made by: (i) reacting bromine with a solution of 4-acetamido-cyclohexanone in water to produce 2-bromo-4-acetamido-cyclohexanone; (ii) after step (i), adding thiourea to produce 6-acetyl amino- 2-amino-4,5,6,7-tetrahydro-benzthiazole; (iii) after step (ii), adding an aqueous solution of hydrobromic acid to produce 2,6-diamino-4,5,6,7-tetrahydro-benzthiazole dihydrobromide; and (iv) after step (iii), isolating 2,6-diamino-4,5,6,7 -tetrahydro-benzthiazole.